Biodexa Pharmaceuticals (BDRX) Tax Provisions (2016 - 2024)

Biodexa Pharmaceuticals (BDRX) reported Tax Provisions of $160437.7 for Q4 2024, down 65.11% sequentially from $459787.9 in Q4 2022.

Biodexa Pharmaceuticals (BDRX) Tax Provisions (2016 - 2024) Analysis & Trends

Biodexa Pharmaceuticals (BDRX) has 7 years of Tax Provisions data on file, last reported at $160437.7 in Q4 2024.

For the quarter ending Q4 2024, Tax Provisions changed N/A year-over-year to $160437.7; the trailing twelve-month figure through Dec 2024 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $138443.6, down 56.85% from the prior year.
Tax Provisions slipped to $160437.7 in Q4 2024, from $459787.9 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $786988.8 in Q4 2020 to a low of $160437.7 in Q4 2024.
A 4-year average of $431837.7 and a median of $416776.7 in 2022 frame the typical range for Tax Provisions.
Across the five-year window, Tax Provisions slumped 59.58% in 2021 and soared 44.53% in 2022, its largest moves.
Tracing BDRX's Tax Provisions over 4 years: stood at $786988.8 in 2020, then tumbled by 59.58% to $318130.5 in 2021, then soared by 44.53% to $459787.9 in 2022, then tumbled by 65.11% to $160437.7 in 2024.
Business Quant data shows BDRX's Tax Provisions at $160437.7 in Q4 2024, $459787.9 in Q4 2022, and $416776.7 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	125,146.46
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	31.86 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	179.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Biodexa Pharmaceuticals	18.43 Bn	18.43 Bn	-	-

Download Data